CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

A cell-based gene therapy to treat adults with large B-cell lymphoma (LBCL) has received FDA approval. Lisocabtagene maraleucel, marketed as Breyanzi, is a chimeric antigen receptor T-cell (CAR-T) therapy indicated for patients who haven ’t responded to or have relapsed after at least 2 other systemic treatments.
Source: JAMA - Category: General Medicine Source Type: research